Wald: it is planning to buy xinjinquan shares by issuing shares and paying cash. The trading of shares is suspended

Survival Rules for Turbulent Times: A Compilation of the 20 Most Unmissable Core Insights from the 2026 Tsinghua PBCSF Forum

A dialogue between Zhu Min, former Deputy Governor of the People's Bank of China and former Vice Managing Director of the International Monetary Fund; Michael Spence, 2001 Nobel Prize winner in Economics and Philip H. Knight Professor Emeritus of Management at Stanford Graduate School of Business; and Masaaki Shirakawa, former Governor of the Bank of Japan, at the 2026 Tsinghua PBCSF Global Finance Forum.

Unpacking China | Key Chinese Firms to Watch This Week （16/08/2026-22/08/2026）

X  Amid fast-paced changes that fill the business community with excitement, angst and trepidation, EqualOcean will publish a series of roundup articles to document the major events related to Chinese companies going global every week.

Kanghong’s Conbercept Receives Marketing Authorization in Guyana

Kanghong Pharmaceutical (康弘药业) said its subsidiary Kanghong Bioscience had received a drug registration certificate from Guyana’s Food and Drug Department for conbercept ophthalmic injection, marketed under the brand name Lumitin (朗沐).

SHEIN Reportedly Targets US$26–27 Billion Valuation in Hong Kong IPO

SHEIN (希音), the China-founded global fashion and lifestyle retailer, is reportedly seeking a valuation of US$26 billion to US$27 billion in a planned Hong Kong initial public offering, a sharp reduction from the US$98.2 billion private-market valuation disclosed for its 2022 fundraising round.

Pony.ai’s Robotaxi Revenue Rises 691% as Overseas Deployment Pipeline Tops 4,000 Vehicles

Pony.ai reported a sharp acceleration in Robotaxi revenue in the second quarter of 2026, while outlining planned and potential overseas deployments exceeding 4,000 vehicles—signalling the company’s push to turn its China operating experience into a broader international business.